Syndax Pharmaceuticals Q4 2024 Earnings Report $12.95 -0.15 (-1.15%) As of 03/14/2025 04:00 PM Eastern Earnings HistoryForecast Syndax Pharmaceuticals EPS ResultsActual EPS-$1.10Consensus EPS -$0.31Beat/MissMissed by -$0.79One Year Ago EPSN/ASyndax Pharmaceuticals Revenue ResultsActual Revenue$7.68 millionExpected Revenue$86.32 millionBeat/MissMissed by -$78.64 millionYoY Revenue GrowthN/ASyndax Pharmaceuticals Announcement DetailsQuarterQ4 2024Date3/3/2025TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSNDX Earnings History Remove Ads Syndax Pharmaceuticals Earnings HeadlinesResearch Analysts Issue Forecasts for SNDX FY2025 EarningsMarch 8, 2025 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at HC WainwrightMarch 7, 2025 | americanbankingnews.comLying in hospital… staring at the light"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.March 15, 2025 | Porter & Company (Ad)What is B. Riley's Forecast for SNDX Q3 Earnings?March 7, 2025 | americanbankingnews.comBrokers Set Expectations for SNDX Q1 EarningsMarch 7, 2025 | americanbankingnews.comQ1 Earnings Forecast for SNDX Issued By HC WainwrightMarch 7, 2025 | americanbankingnews.comSee More Syndax Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Syndax Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Syndax Pharmaceuticals and other key companies, straight to your email. Email Address About Syndax PharmaceuticalsSyndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.View Syndax Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles These 3 Q1 Earnings Winners Will Go HigherAnalysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before Earnings Upcoming Earnings Micron Technology (3/20/2025)PDD (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025)NIKE (3/20/2025)Cintas (3/26/2025)Paychex (3/26/2025)Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
